(Q60588004)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

editorial

0 references

title

The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Alfonso Quintás-Cardama

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Don L Gibbons

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Hagop Kantarjian

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Jorge Cortes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

5 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

293-299

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

6 February 2020

cites work

1 reference

12 December 2020

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

12 December 2020

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

1 reference

12 December 2020

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

12 December 2020

Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism

1 reference

12 December 2020

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

12 December 2020

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

12 December 2020

Crystal structure of the T315I mutant of AbI kinase

1 reference

12 December 2020

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

12 December 2020

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

1 reference

12 December 2020

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

1 reference

12 December 2020

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

12 December 2020

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

12 December 2020

Rational design of inhibitors that bind to inactive kinase conformations

1 reference

12 December 2020

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

1 reference

12 December 2020

A myristoyl/phosphotyrosine switch regulates c-Abl

1 reference

12 December 2020

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

1 reference

12 December 2020

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

1 reference

12 December 2020

AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance

1 reference

12 December 2020

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

1 reference

12 December 2020

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

1 reference

12 December 2020

Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

1 reference

12 December 2020

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

1 reference

12 December 2020

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?

1 reference

12 December 2020

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

12 December 2020

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

1 reference

12 December 2020

Activation of tyrosine kinases by mutation of the gatekeeper threonine

1 reference

12 December 2020

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

1 reference

12 December 2020

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

1 reference

12 December 2020

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

12 December 2020

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

12 December 2020

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

12 December 2020

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

12 December 2020

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.

1 reference

12 December 2020

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

12 December 2020

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.26225

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21732333%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference